A Phase 3 interventional study of Axillary Lymph Node Dissection with Immediate Lymphatic Reconstruction and Axillary Lymph Node Dissection without Immediate Lymphatic Reconstruction in Breast Cancer Lymphedema, sponsored by Memorial Sloan Kettering Cancer Center. Active, not recruiting at 7 sites in United States. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-27.
Sponsored by Memorial Sloan Kettering Cancer Center · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Breast Cancer Lymphedema with a site in United States — 8 open to participants now, 10 under way, 1 of them phase 3. Breast Cancer Lymphedema · United States.
Among the 15 studies in Breast Cancer Lymphedema with a site in United States, this one is the 2nd largest by enrollment of the 12 interventional ones that give a count, is one of 4 that started in 2020, is the only one in phase 3, and was the 2nd registered.
124 studies on the registry are indexed under Breast Cancer Lymphedema; 39 are open to participants now.
Browse Breast Cancer Lymphedema studies →8 of the 15 studies in Breast Cancer Lymphedema with a site in United States are open now. Recruiting first, the newest first:
University of South Florida · Sites in United States
Ages 18–75 · Women only
University of Florida · Sites in United States
Ages 18–99
Texas Woman's University · Sites in United States
Ages 18+ · Women only
University Hospital, Basel, Switzerland · Sites in United States, Austria, Belgium and 12 more countries
Ages 18+
Stanford University · Sites in United States
Ages 18–75 · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 24 Breast Cancer Lymphedema studies recruiting now, 8 (33%) set no upper age limit and 9 (38%) stop at 75 or younger; none take children under 18; 2 take healthy volunteers.
This study: 18 Years to 75 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 4 started in 2020.
This study's enrollment of 180 is above the median of 48 across 97 interventional studies indexed under Breast Cancer Lymphedema.
Median enrollment 45 across the 12 interventional studies, 261 across the 3 observational. Of the 5 that completed or were terminated, 3 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 15 have an industry lead sponsor. The 9 most frequent:
Memorial Sloan Kettering Cancer Center is the lead sponsor of 1,964 studies on the registry; 325 are open to participants now.
Of its 135 completed or terminated interventional studies of FDA-regulated products, 71 (53%) have results posted.
Memorial Sloan Kettering Cancer Center has 1 study filed under Breast Cancer Lymphedema — fewer than ten, so there is no comparison to draw.
5 of the studies in Breast Cancer Lymphedema with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04241341Phase 3Memorial Sloan Kettering Cancer CenterDoes Immediate Lymphatic Reconstruction Decrease the Risk of Lymphedema After Axillary Lymph Node Dissection | 2027-01 |
| NCT05366699Stanford UniversityLYMPHA Procedure for the Prevention of Lymphedema After Axillary Lymphadenectomy | 2027-06-01 |
| NCT05326165Massachusetts General HospitalEarly Intervention | 2027-06-30 |
| NCT05890677University Hospital, Basel, SwitzerlandThe LYMPH Trial - Microsurgical Versus Conservative Treatment of Chronic Breast Cancer Associated Lymphedema | 2027-09 |
| NCT05142800Massachusetts General HospitalScreening For BCRL In Targeted Therapy For Breast Cancer | 2027-09-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 15 studies in Breast Cancer Lymphedema with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The researchers are doing this study to see if having immediate lymphatic reconstruction after axillary lymph node dissection (ALND) can decrease the development of lymphedema, a side effect of ALND. Other purposes of the study include:
Comparing the approach of immediate lymphatic reconstruction after ALND with the approach of ALND alone Looking at whether having immediate lymphatic reconstruction after ALND improves a person's quality of life Seeing if adding standard of care radiation therapy to either study approach (immediate lymphatic reconstruction after ALND or ALND alone) has an effect on development of lymphedema
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Procedure: Axillary Lymph Node Dissection with Immediate Lymphatic Reconstruction · Other: quality-of-life questionnaires · Other: measured by arm volume
Procedure: Axillary Lymph Node Dissection without Immediate Lymphatic Reconstruction · Other: quality-of-life questionnaires · Other: measured by arm volume
Axillary Lymph Node Dissection with Immediate Lymphatic Reconstruction
Current standard treatment at Memorial Sloan Kettering \[MSK\]).
Four validated patient reported outcome measures (PROMs): the Upper Limb Lymphedema-27 (ULL-27), the Quality of Life Measure for Limb Lymphedema (LYMQOL), the Center for Epidemiologic Studies Depression Scale-Revised (CESD-R), and the Beck Anxiety Inventory (BAI). Study participants will undergo standard lymphedema measurements and quality-of-life questionnaires at baseline before ALND and postoperatively at 6 weeks (+/- 30 days) and at 6, 12, 18, and 24 months (+/- 30 days). If patients are unable to complete their questionnaires at the time of their in-office visit, a link to the questionnaires in REDCap will be emailed to them.
Bilateral arm volumes will be measured with sequential circumferential measurements with the truncated cone formula. If a patient cannot return to Manhattan for these assessments but is seen by a lymphedema therapist in a regional location or at an institution outside of MSK as part of their routine cancer treatment, this data can be used in the final analysis
the number of patients that had a decrease incidence of lymphedema
as measured by arm volume will be a ≥10% increase in arm volume
Time frame: up to 2 years
Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
Started Jan 2020 (actual). Primary completion is estimated for Jan 2027, 84 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Memorial Sloan Kettering Cancer Center →